BTG plc’s U.S. Biocompatibles Biz Coughs Up $36 Million to Settle Justice Dept. Beef

Published: Oct 07, 2016

BTG said today that it agreed to pay the U.S. Justice Dept. $36 million (£28.4 million) to settle a probe into the marketing of the LC Bead embolization microspheres made by its Biocompatibles subsidiary.

The Justice Dept. launched the probe in July 2014, saying it would investigate the marketing practices for LC Bead from 2003 to 2011, covering a period before the January 2011 buyout of Biocompatibles by the British drug-delivery giant. The settlement does not include a corporate integrity agreement, BTG said.

Back to news